<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marshall J Glesby, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rajesh T Gandhi, MD, FIDSA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 24, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Prior to the availability of effective antiretroviral therapy (ART), severe wasting and decreased levels of cholesterol were common metabolic abnormalities described in advanced acquired immunodeficiency syndrome (AIDS) [<a href="#rid1">1</a>]. With the introduction of effective ART, descriptions of patients with body shape abnormalities such as central fat accumulation and peripheral fat loss emerged [<a href="#rid2">2,3</a>]. The term "human immunodeficiency virus (HIV)-associated lipodystrophy syndrome" was coined, but it soon became clear that there was not a single syndrome but rather the co-occurrence of phenotypes that varies from person to person. It may be that some individuals will present with pure lipoatrophy, others have fat accumulation which may present in a variety of ways, and a subset of patients have a mixed picture of both morphologic features [<a href="#rid4">4-8</a>]. Thus, it is more valid to consider the individual components separately. These morphologic abnormalities can also be associated with disorders in glucose and lipid metabolism [<a href="#rid9">9-11</a>].</p><p>Risk factors, clinical manifestations, and diagnosis of HIV-associated lipodystrophy will be discussed here. The management and treatment of these patients is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3700.html" rel="external">"Treatment of HIV-associated lipodystrophy"</a>.)</p><p>The association between lipodystrophy and metabolic abnormalities is also discussed briefly in this topic. Additional detail on the epidemiology and management of dyslipidemia and disordered glucose metabolism in patients with HIV is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">"Epidemiology of cardiovascular disease and risk factors in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3739.html" rel="external">"Management of cardiovascular risk (including dyslipidemia) in patients with HIV"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>Controversy exists about how frequently the lipodystrophy syndrome occurs, with estimates ranging from 10 percent to more than 80 percent [<a href="#rid12">12-15</a>]. The wide variation in prevalence may be partly related to differences in definitions or methodology (eg, patient report versus objective measurements) as well as differences in host factors, including geography, age, genetics, lifestyle factors, and specific antiretroviral use and duration of treatment [<a href="#rid16">16-18</a>]. The presumption is that the prevalence will be lower with the increased use of newer antiretroviral drugs, which are much less prone to contribute to this disorder, but there are few studies looking at the contemporary prevalence of the syndrome [<a href="#rid19">19</a>].</p><p>Moreover, lipoatrophy and fat accumulation appear to be different syndromes with different risk factors and differing prevalences. This point was well illustrated in one study of 452 patients with HIV who were followed over one year to assess risk factors for progression of morphologic abnormalities [<a href="#rid16">16</a>]. Lipoatrophy was defined as a triceps skin-fold measurement less than the 10<sup>th</sup> percentile in the National Health and Nutrition Examination Survey for sex and age. Fat accumulation was defined as a waist-to-hip ratio of &gt;0.95 for men and of &gt;0.85 for women as a surrogate for intra-abdominal fat. The study demonstrated the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The baseline prevalence for lipoatrophy, fat deposition, and a mixed picture was 35, 44, and 14 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of developing new lipoatrophy was increased in patients with low baseline triceps skin-fold values and smaller hips; higher HIV ribonucleic acid (RNA) levels and use of <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a> or <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">stavudine</a> were also predictors of risk. Abacavir is not generally thought to induce lipoatrophy, so this apparent association may represent attempts by clinicians to change antiretroviral therapy to agents thought less likely to contribute to lipoatrophy. (See <a class="local">'Risk factors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, the risk of fat deposition was greater in women and occurred more frequently among those study participants who had higher levels of body fat or higher triglyceride levels at baseline. (See <a class="local">'Risk factors'</a> below.)</p><p></p><p>The discussion below will address both lipoatrophy and fat accumulation as two separate and distinct entities.</p><p class="headingAnchor" id="H5"><span class="h1">LIPOATROPHY</span></p><p class="headingAnchor" id="H2269730"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>While fat atrophy is difficult to quantify, it is quite easily recognized. The main risk factor for lipoatrophy is exposure to thymidine analogue nucleoside reverse transcriptase inhibitors (NRTIs), predominantly <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">stavudine</a>, but also <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a>. The risk with other agents or classes of antiretroviral therapy (ART), such as protease inhibitors or non-nucleoside reverse transcriptase inhibitors (NNRTIs), is less evident in the absence of concurrent thymidine analogue use. HIV disease severity (such as baseline CD4 cell count and viral load) and certain host factors (age, baseline body type) may also influence the risk of lipoatrophy.</p><p class="headingAnchor" id="H2270602"><span class="h3">Exposure to NRTIs</span><span class="headingEndMark"> — </span>Data suggest that exposure to certain nucleoside reverse transcriptase inhibitors (NRTIs) is the major factor associated with lipoatrophy [<a href="#rid5">5,12,16,20-24</a>]. Trials comparing different antiviral regimens suggest that thymidine analogs (in particular <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">stavudine</a>, but also <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a>) play an important role in pathogenesis of lipoatrophy [<a href="#rid21">21,22,25-29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In an open-label trial in which 237 patients with HIV initiating antiretroviral therapy (ART) were randomly assigned to <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a> or <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">stavudine</a>, each combined with <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> and <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a>, a higher proportion of patients taking stavudine developed clinical signs of lipoatrophy (38 versus 5 percent with abacavir) as assessed by anthropometric measurements at 96 weeks [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a trial comparing <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">stavudine</a> and <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a> (TDF), each in combination with <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> and <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a>, patients randomly assigned to tenofovir demonstrated normal limb fat at 144 weeks of therapy compared with a significant decline in lower limb fat mass in nearly 50 percent of patients receiving stavudine [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a subset of patients participating in an open-label randomized trial comparing TDF-emtricitabine and <a class="drug drug_general" data-topicid="10221" href="/z/d/drug information/10221.html" rel="external">zidovudine-lamivudine</a>, each in combination with <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a>, total limb fat at week 48, as measured by dual energy x-ray absorptiometry (DEXA), was less with <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a> than tenofovir (mean 6.9 versus 8.0 kg fat) [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DEXA scans were also performed every 16 weeks on a subset of 157 antiretroviral-naïve patients who were randomly assigned to <a class="drug drug_general" data-topicid="9685" href="/z/d/drug information/9685.html" rel="external">nelfinavir</a>, <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a>, or both, combined with <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a> and <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> or <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">stavudine</a> and <a class="drug drug_general" data-topicid="9351" href="/z/d/drug information/9351.html" rel="external">didanosine</a> [<a href="#rid27">27</a>]. After week 32, limb fat declined by 2 percent per year in the zidovudine plus lamivudine arm compared with 19 percent per year in the stavudine plus didanosine arm.</p><p></p><p>Other studies have only noted an association between lipoatrophy and duration of NRTI use [<a href="#rid30">30,31</a>]. The risk of lipoatrophy with thymidine analogue use may be due to NRTI-induced inhibition of mitochondrial deoxyribonucleic acid (DNA) polymerase gamma and mitochondrial toxicity. Surgical biopsy specimens of subcutaneous adipose tissue in patients with lipoatrophy are characterized by mitochondrial DNA depletion, inflammation, and signs of apoptosis [<a href="#rid32">32,33</a>]. Neither <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">stavudine</a> nor <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a> is recommended for use in patients with HIV. (See  <a class="medical medical_review" href="/z/d/html/3766.html" rel="external">"Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load", section on 'Other considerations for regimen selection'</a>.)</p><p class="headingAnchor" id="H95344288"><span class="h3">Exposure to other ART classes</span><span class="headingEndMark"> — </span>Agents from antiretroviral classes other than the NRTIs have been associated with lipoatrophy in some studies, although mainly because of concurrent use with offending NRTIs. Some studies have suggested that although NRTI use contributes to fat wasting, protease inhibitors may act synergistically with NRTIs [<a href="#rid23">23,24</a>]. However, therapy with protease inhibitors alone does not appear to lead to lipoatrophy [<a href="#rid8">8</a>]. Similarly, in a metabolic substudy of a trial evaluating various ART regimens (ACTG 5142), the incidence of lipoatrophy was higher with <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a> plus two NRTIs compared with lopinavir plus two NRTIs or efavirenz plus lopinavir, but the association between efavirenz and lipoatrophy was mainly in combination with <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">stavudine</a> or <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a>, not TDF [<a href="#rid34">34</a>]. Other studies have also suggested that the role of efavirenz in the development of lipoatrophy is minimal and mainly directed by the nucleoside analogs that form the backbone [<a href="#rid35">35</a>]. Other studies suggest that integrase inhibitors do not contribute to lipoatrophy [<a href="#rid36">36,37</a>]. Risk of limb-fat loss with <a class="drug drug_general" data-topicid="16494" href="/z/d/drug information/16494.html" rel="external">rilpivirine</a> appears similar to that with efavirenz [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H2270284"><span class="h3">Host and viral factors</span><span class="headingEndMark"> — </span>HIV disease severity and certain host factors may interact to result in lipoatrophy. Characteristics that have been associated with lipoatrophy, either self-reported or objectively measured, include increased age, lower fat mass at baseline, higher baseline viral loads, and lower CD4 cell counts at initiation of HIV therapy [<a href="#rid16">16,39,40</a>]. However, not all studies using objective measurements of lipoatrophy have confirmed a link with age or lower CD4 cell counts [<a href="#rid41">41,42</a>].</p><p>Although fat atrophy is often associated with weight loss, there is no apparent association with nutrition status.</p><p>There has also been an epidemiological association between coinfection with hepatitis C virus (HCV) and the development of lipoatrophy in individuals with HIV [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Lipoatrophy involves the loss of subcutaneous fat in the face, arms, legs, abdomen, and/or buttocks [<a href="#rid16">16,17,44</a>]. In contrast to AIDS-associated wasting, lipoatrophy is distinguished by the preferential loss of subcutaneous fat tissue without substantial loss of lean tissue mass in patients who are clinically responding to ART [<a href="#rid5">5,45</a>].</p><p>Facial lipoatrophy is characterized by loss of the buccal and/or temporal fat pads, leading to facial skeletonization with concave cheeks, prominent nasolabial folds, periorbital hollowing, and visible facial musculature  (<a class="graphic graphic_picture graphicRef77131" href="/z/d/graphic/77131.html" rel="external">picture 1</a>) [<a href="#rid46">46</a>]. Atrophy of the buccal fat pads is of particular concern to patients since it gives the appearance of facial wasting and can have an impact on self-esteem; lipoatrophy may also contribute to stigma as it is recognized to be associated with HIV infection [<a href="#rid47">47</a>].</p><p>Lipoatrophy is also readily apparent in the extremities, as veins and musculature become more prominent with the loss of supporting subcutaneous fat. Truncal fat atrophy may be detectable by a minimal amount of subcutaneous "pinchable" fat in the abdomen, but it is often less obvious than lipoatrophy elsewhere, especially if there is fat deposition within the abdominal cavity. In this situation, waist circumference may not change, as the intraabdominal volume may be increasing at the same time as the subcutaneous fat is decreasing  (<a class="graphic graphic_figure graphicRef72033" href="/z/d/graphic/72033.html" rel="external">figure 1</a>). This may only be determined by computed tomography (CT)  (<a class="graphic graphic_diagnosticimage graphicRef116436" href="/z/d/graphic/116436.html" rel="external">image 1</a>) or magnetic resonance imaging (MRI) scans, which can distinguish intraabdominal and subcutaneous fat; however, these scans are rarely performed for this purpose as a part of clinical care.</p><p>Studies evaluating body composition following initiation of ART have suggested that limb fat increases during the first few months of treatment and then progressively decreases over the subsequent few years [<a href="#rid12">12,48</a>]. A substantial amount of fat may need to be lost before lipoatrophy is clinically apparent, as this depends on the amount of fat that was present at baseline. In one study of patients with HIV who underwent DEXA to quantify fat loss, a limb fat loss of 30 percent was needed for it to be visually evident [<a href="#rid49">49</a>].</p><p>Fat accumulation coexists with lipoatrophy in a number of patients. In a classic case of fat atrophy and fat accumulation, the abdominal wall of such an individual would have scant pinchable fat but would have a high waist circumference with increased intraabdominal fat [<a href="#rid5">5,50</a>]. Dyslipidemia and disordered glucose metabolism are also often seen in patients with HIV-associated lipoatrophy. (See <a class="local">'Metabolic abnormalities'</a> below and  <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">"Epidemiology of cardiovascular disease and risk factors in patients with HIV"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Diagnosis and evaluation</span><span class="headingEndMark"> — </span>We routinely evaluate patients with HIV on ART for the development of lipoatrophy. The diagnosis of HIV-associated lipoatrophy is made by detection of characteristic findings on visual inspection and physical exam (see <a class="local">'Clinical features'</a> above). Patient self-report may be an early and the best indicator of body shape changes. Additionally, it may be possible to diagnose truncal fat atrophy by a minimal amount of pinchable (subcutaneous) fat on the abdomen.</p><p>Anthropometric evaluations of limb circumferences and skin folds provide data regarding body shape but can vary depending on the evaluator. Objective quantification of fat can be obtained by CT, MRI, and DEXA scanning, but these are usually limited to research venues and offer no additional benefit to patient self-report and physical examination [<a href="#rid8">8</a>], as they are difficult to interpret and norms are not available.</p><p>Various staging scales have been suggested to characterize the severity of facial atrophy, but many of these are subjective [<a href="#rid51">51-53</a>]. Intraobserver variability was satisfactory with one scale that incorporated objective anatomic findings (eg, malar depression, buccal extension, nasolabial ridge) [<a href="#rid54">54</a>]. Nevertheless, there are no widely accepted objective techniques for assessing malar atrophy.</p><p>Although patients with HIV should be routinely assessed for abnormalities in lipid and glucose metabolism regardless of lipodystrophy, the presence of lipoatrophy should prompt such evaluation if not already performed. (See <a class="local">'Metabolic abnormalities'</a> below and  <a class="medical medical_review" href="/z/d/html/3739.html" rel="external">"Management of cardiovascular risk (including dyslipidemia) in patients with HIV", section on 'Assessing cardiovascular risk'</a>.)</p><p>The main differential diagnosis of HIV-associated lipoatrophy is severe wasting, in which there is loss of both subcutaneous fat and lean tissue, and can be difficult to distinguish from fat atrophy in a thin individual. However, severe wasting is rarely seen in the setting of effective ART.</p><p class="headingAnchor" id="H12"><span class="h1">FAT ACCUMULATION</span></p><p class="headingAnchor" id="H2272511"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Although fat accumulation is mainly described in patients with HIV on antiretroviral therapy (ART), the use of specific antiretroviral agents has not been clearly implicated, and fat accumulation can occur to some degree with any regimen. Other risk factors associated with the development of fat accumulation/deposition in treated patients with HIV include mainly host instead of viral factors.</p><p>Fat accumulation has been described since the introduction of combination ART [<a href="#rid9">9,16,44,55-57</a>], but not all studies have found a clear association between ART and increasing body mass index (BMI) or waist and hip circumferences [<a href="#rid31">31,58</a>]. Furthermore, no particular antiretroviral agent or class has been specifically implicated in the development of fat accumulation. The use of protease inhibitor therapy, specifically, was initially thought to lead to the development of fat accumulation [<a href="#rid44">44,55,59</a>]. However, in studies that have replaced protease inhibitor agents with alternative ART (eg, non-nucleoside reverse transcriptase inhibitors [NNRTIs] or integrase inhibitors), there has been no observed decrease in visceral fat [<a href="#rid60">60-62</a>]. In randomized controlled trials comparing boosted protease inhibitors with other agents as initial therapy for treatment-naïve patients (<a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">atazanavir</a> versus <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a> and atazanavir or <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">darunavir</a> versus <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">raltegravir</a>), gains in abdominal and limb fat over time with protease inhibitors and the comparators were similar [<a href="#rid36">36,63</a>]. In addition, fat accumulation has also been described in patients on ART who had never been exposed to a protease inhibitor [<a href="#rid45">45,57</a>]. As an example, in a randomized study of 422 antiretroviral-naïve patients initiating ART, there was no difference in the development of regional fat between any of the three treatment arms, which were a protease inhibitor with nucleoside reverse transcriptase inhibitor (NRTI) backbone, a NNRTI with NRTI backbone, or a protease inhibitor plus a NNRTI [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/z/d/html/3700.html" rel="external">"Treatment of HIV-associated lipodystrophy", section on 'Prevention'</a>.)</p><p>With increased use of integrase inhibitors, an association between weight gain and <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> or bictegravir use has been identified, although it is unknown whether this weight gain is related to fat accumulation [<a href="#rid65">65</a>]. Similarly, use of the <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">tenofovir alafenamide</a> formulation of tenofovir has been associated with weight gain relative to the <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a> formulation [<a href="#rid66">66,67</a>]. (See  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach", section on 'Commonly used agents'</a>.)</p><p>A higher risk of developing fat deposition has also been described with increasing age, female sex, elevated baseline triglycerides, and higher body fat percentage [<a href="#rid16">16</a>]. Some evidence has suggested that fat deposition in patients with HIV may reflect the epidemic of obesity occurring in the general population, rather than an effect of HIV infection or ART. As such, the appearance of lipodystrophy may be obesity with concurrent fat atrophy. One study that compared patients with HIV with controls without HIV (Fat Redistribution and Metabolic Abnormalities in HIV or FRAM study) suggested that overall fat deposition was no more common in individuals with HIV [<a href="#rid5">5,50</a>]. It also showed that the prevalence of cervical dorsal fat pad (buffalo hump) was similar in controls with and without HIV; however, the size of the buffalo hump may be significantly greater in individuals with HIV. Another study demonstrated that BMI, as well as waist and hip circumference, increased over five years among 266 women without HIV but remained stable in 942 women with HIV [<a href="#rid58">58</a>]. By contrast, in the Multicenter AIDS Cohort Study, men with HIV had more rapid increases in waist circumference over five years than men without HIV [<a href="#rid31">31</a>]. It should be noted that neither BMI or waist or hip measurements are specific for visceral (intraabdominal) fat.</p><p>There does seem to be an association between fat accumulation and nutrition status. Studies that have examined the diet of individuals with HIV, with and without visceral adiposity, have suggested that poorer quality of diet, as measured by amount of fiber, are associated with the occurrence of fat deposition [<a href="#rid68">68,69</a>]. The increasing frequency of obesity in the population with HIV may obscure the ability to detect fat accumulation.</p><p class="headingAnchor" id="H14"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Abdominal fat accumulation is an excess of visceral adipose tissue (VAT) that results in an increase in abdominal girth. "Buffalo hump" results from an accumulation of fat in the dorsocervical area. Fat accumulation can also occur in the trunk and upper chest. Both males and females may develop deposition of extra breast fat or symmetrical deposits of subcutaneous fat nodules on their trunk and extremities (eg, lipomas).</p><p>In many cases, it may be difficult to distinguish this syndrome from simple obesity, in which visceral fat is also accompanied by increased amounts of subcutaneous fat in the abdominal wall  (<a class="graphic graphic_figure graphicRef72033" href="/z/d/graphic/72033.html" rel="external">figure 1</a>). HIV-associated fat accumulation is primarily visceral fat deposition with normal or decreased (but not increased) amounts of subcutaneous fat [<a href="#rid5">5,50</a>]. Visceral or intraabdominal fat is not palpable externally; thus, pinchable fat at the waistline is a helpful clinical distinguishing feature of subcutaneous fat. A patient with HIV and both lipoatrophy and fat deposition would have minimal pinchable fat at the waistline despite a possibly increased waist circumference. Computed tomography (CT) or magnetic resonance imaging (MRI) can distinguish between visceral and subcutaneous fat but are rarely performed for this purpose  (<a class="graphic graphic_diagnosticimage graphicRef116436" href="/z/d/graphic/116436.html" rel="external">image 1</a>).</p><p>Studies evaluating body composition following initiation of ART have suggested that central fat increases soon after initiation of ART, within the first several months, but may subsequently level off [<a href="#rid12">12,48</a>].</p><p>In addition to fat accumulation in pre-existing fatty tissue, fat deposition can also occur in the muscles and liver.</p><p>Lipoatrophy coexists with fat accumulation in a number of patients. Dyslipidemia and disordered glucose metabolism are also often seen in patients with HIV-associated fat accumulation. (See <a class="local">'Metabolic abnormalities'</a> below and  <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">"Epidemiology of cardiovascular disease and risk factors in patients with HIV"</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Diagnosis and evaluation</span><span class="headingEndMark"> — </span>We routinely evaluate patients with HIV on ART for the development of fat accumulation. The diagnosis of HIV-associated fat accumulation is made by detection of characteristic findings on visual inspection and physical examination (see <a class="local">'Clinical features'</a> above). Abdominal obesity can be detected and quantified by simple measures, including measurement of the waist circumference. An abdominal circumference &gt;102 cm for men and &gt;88 cm for women is considered abnormal and considered more accurate than a waist/hip circumference ratio [<a href="#rid70">70</a>]. If the ratio of waist/hip measure increased because of decrease in hip circumference, it may be mistakenly interpreted as increasing abdominal girth.</p><p>HIV-associated abdominal fat accumulation is predominantly visceral but appears similar to simple obesity, in which visceral fat is also accompanied by increased amounts of subcutaneous fat in the abdominal wall  (<a class="graphic graphic_figure graphicRef72033" href="/z/d/graphic/72033.html" rel="external">figure 1</a>). An inability to pinch the fat in the setting of abdominal obesity is suggestive of visceral fat accumulation, which cannot be palpated externally. Quantitative measurements of visceral adipose tissue can be assessed by CT or MRI, but these are usually done in research trials only. Dual x-ray absorptiometry (DEXA) measures trunk fat but cannot distinguish between visceral and subcutaneous adipose tissue and is not recommended.</p><p>Keeping a log of weight, BMI, and measures of waist, hip, and mid-upper-arm circumferences can be useful. Measuring height and weight to calculate the BMI, which can be followed over time, may also be useful to detect progressive changes, although patients with fat redistribution can have increased visceral fat but a normal or only modestly elevated BMI. If the BMI is stable and the waist circumference is increasing, this strongly suggests that lipoatrophy is also occurring. It may also be useful to follow the evolution of body shape changes or places where the body shape is disproportionate.</p><p>Although patients with HIV should be routinely assessed for abnormalities in lipid and glucose metabolism regardless of lipodystrophy, the presence of fat accumulation should prompt such evaluation if not already performed. (See <a class="local">'Metabolic abnormalities'</a> below and  <a class="medical medical_review" href="/z/d/html/3739.html" rel="external">"Management of cardiovascular risk (including dyslipidemia) in patients with HIV", section on 'Assessing cardiovascular risk'</a>.)</p><p>Simple obesity as opposed to HIV-associated fat accumulation is suggested by the presence of high BMI with large abdominal girth and pinchable trunk fat. In patients with HIV and fat accumulation in the dorsocervical region (buffalo hump), an alternative possible cause is Cushing’s syndrome, which can be distinguished by the presence of hypercortisolism. (See  <a class="medical medical_review" href="/z/d/html/151.html" rel="external">"Establishing the diagnosis of Cushing syndrome"</a>.)</p><p class="headingAnchor" id="H18746734"><span class="h1">METABOLIC ABNORMALITIES</span><span class="headingEndMark"> — </span>Both lipoatrophy and fat accumulation have been associated with abnormalities in glucose and lipid metabolism, even in the absence of frank obesity.</p><p>The development of visceral obesity, insulin resistance, and atherogenic lipid profiles raises concern regarding a potential increased risk of cardiovascular disease in individuals with HIV, since these are all well-established risk factors [<a href="#rid70">70,71</a>]. Visceral adiposity itself has also been independently associated with subclinical atherosclerosis in males and females with HIV [<a href="#rid72">72,73</a>]. (See  <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">"Epidemiology of cardiovascular disease and risk factors in patients with HIV"</a>.)</p><p class="headingAnchor" id="H3365455105"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>The association between lipodystrophy and metabolic abnormalities may be related to adipokines. Adipocytes secrete hormones, such as adiponectin, leptin, and resistin, which are involved in metabolic pathways.</p><p class="bulletIndent1"><span class="glyph">●</span>In humans, decreased adiponectin levels are associated with insulin resistance and type 2 diabetes mellitus [<a href="#rid74">74</a>]. In patients with HIV, adiponectin levels are decreased in patients with peripheral lipoatrophy and central lipohypertrophy [<a href="#rid75">75</a>]. It has been postulated that decreased adipocyte differentiation may lead to decreased adiponectin levels and insulin resistance in patients with HIV [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Leptin levels are lower in the subgroup of patients with significant lipoatrophy compared with patients with HIV and without lipoatrophy [<a href="#rid77">77</a>]. In mice, leptin deficiency is associated with insulin resistance. However, the absolute threshold of leptin deficiency that is associated with metabolic abnormalities is unclear.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment-naïve patients who developed significant body composition and metabolic changes on antiretroviral therapy were found to have a single nucleotide polymorphism in the resistin gene, which has been linked to diabetes mellitus in patients who are obese [<a href="#rid78">78,79</a>].</p><p></p><p>Whether metabolic abnormalities are due to reduced adipose tissue mass or a change in hormone expression in adipose tissue is unknown [<a href="#rid76">76</a>]. One study has also suggested that genetic polymorphisms involved in apoptosis and adipocyte metabolism may influence the emergence of lipoatrophy versus fat accumulation [<a href="#rid80">80</a>]. Another study examining the effect of mitochondrial haplogroups did not find any association with any specific changes in anthropomorphic measures [<a href="#rid81">81</a>]. Emerging data suggest that dysregulated microRNAs may play a role in adipose dysfunction and metabolic abnormalities in people with HIV [<a href="#rid82">82</a>]. </p><p class="headingAnchor" id="H18746790"><span class="h2">Abnormal glucose metabolism</span><span class="headingEndMark"> — </span>Fat redistribution may contribute to insulin resistance in individuals with HIV [<a href="#rid83">83,84</a>]. In a study of 41 men with HIV (21 with lipodystrophy and 20 without) and 20 controls without HIV, waist to hip measurement ratio was superior to other body-composition measures in predicting fasting hyperinsulinemia [<a href="#rid83">83</a>]. Another study suggested that the severity of lipoatrophy among patients taking either <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">stavudine</a> or <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a> was associated with an increased risk of insulin resistance [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H18746796"><span class="h2">Dyslipidemia</span><span class="headingEndMark"> — </span>Atherogenic lipid profiles are also associated with body fat changes in individuals with HIV [<a href="#rid48">48</a>]. The relation between regional body fat measurements and lipid levels was examined in the Fat Redistribution and Metabolic Changes in HIV Infection study [<a href="#rid85">85,86</a>]. Proatherogenic lipid profiles were more common in patients with HIV compared to controls without HIV, particularly in association with certain fat redistribution patterns. Both increased visceral fat and decreased subcutaneous leg fat were associated with elevated triglycerides and decreased high-density lipoprotein cholesterol.</p><p class="headingAnchor" id="H1647470200"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111628.html" rel="external">"Society guideline links: Primary care of adults with HIV"</a>.)</p><p class="headingAnchor" id="H37"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> − Despite the commonly used term "HIV-associated lipodystrophy syndrome," it does not describe a single syndrome. Some patients have pure lipoatrophy (fat atrophy), others have fat accumulation which may present in a variety of ways, and still others have a mixed picture of both morphologic features. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> − The exact prevalence of lipoatrophy and fat accumulation is uncertain, with reports ranging from 10 to 80 percent. (See <a class="local">'Introduction'</a> above and <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lipoatrophy</strong> − The main risk factor for lipoatrophy is exposure to thymidine analogue nucleoside reverse transcriptase inhibitors, predominantly <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">stavudine</a> but also <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a>. Lipoatrophy involves the loss of subcutaneous fat in the face, arms, legs, abdomen, and/or buttocks  (<a class="graphic graphic_picture graphicRef77131" href="/z/d/graphic/77131.html" rel="external">picture 1</a>). (See <a class="local">'Lipoatrophy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fat accumulation</strong> − Although fat accumulation is mainly described in patients with HIV on antiretroviral therapy, the use of specific drugs or drug classes has not been clearly implicated, and fat accumulation can occur to some degree with any regimen. Other risk factors include increasing age and female sex. Fat accumulation occurs in the trunk, abdomen, cervical-dorsal area ("buffalo hump"), breasts, and/or upper chest. (See <a class="local">'Fat accumulation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis and evaluation</strong> − The diagnoses of HIV-associated lipoatrophy and fat accumulation are made by the detection of characteristic findings on physical examination. Sequential measures of waist, hip, and mid arm or mid-thigh circumference may be helpful in interpreting changes in body shape or body mass index. (See <a class="local">'Diagnosis and evaluation'</a> above and <a class="local">'Diagnosis and evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolic complications</strong> − Both lipoatrophy and fat accumulation have been associated with abnormalities in glucose and lipid metabolism, even in the absence of frank obesity. (See <a class="local">'Metabolic abnormalities'</a> above.)</p><p></p><p class="headingAnchor" id="H1011035757"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Christine Wanke, MD, who contributed to an earlier version of this topic review.</p><p>UpToDate also gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Grunfeld C, Kotler DP, Hamadeh R, et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86:27.</a></li><li><a class="nounderline abstract_t">Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978.</a></li><li><a class="nounderline abstract_t">Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17 Suppl 1:S141.</a></li><li><a class="nounderline abstract_t">Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23:35.</a></li><li><a class="nounderline abstract_t">Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121.</a></li><li><a class="nounderline abstract_t">Khara M, Conway B. Morphologic changes in HIV-infected men: sorting fact from fiction. J Acquir Immune Defic Syndr 2005; 40:119.</a></li><li><a class="nounderline abstract_t">Mulligan K, Parker RA, Komarow L, et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr 2006; 41:590.</a></li><li><a class="nounderline abstract_t">Wohl DA, McComsey G, Tebas P, et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006; 43:645.</a></li><li><a class="nounderline abstract_t">Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881.</a></li><li><a class="nounderline abstract_t">Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51.</a></li><li><a class="nounderline abstract_t">Wanke CA. Epidemiological and clinical aspects of the metabolic complications of HIV infection the fat redistribution syndrome. AIDS 1999; 13:1287.</a></li><li><a class="nounderline abstract_t">Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17:971.</a></li><li><a class="nounderline abstract_t">Leitz G, Robinson P. The development of lipodystrophy on a protease inhibitor-sparing highly active antiretroviral therapy regimen. AIDS 2000; 14:468.</a></li><li><a class="nounderline abstract_t">Lo JC, Mulligan K, Tai VW, et al. Body shape changes in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:307.</a></li><li><a class="nounderline abstract_t">Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001; 15:231.</a></li><li><a class="nounderline abstract_t">Jacobson DL, Knox T, Spiegelman D, et al. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 2005; 40:1837.</a></li><li><a class="nounderline abstract_t">Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003; 32:48.</a></li><li><a class="nounderline abstract_t">Tien PC, Cole SR, Williams CM, et al. Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr 2003; 34:461.</a></li><li><a class="nounderline abstract_t">Alikhani A, Morin H, Matte S, et al. Association between lipodystrophy and length of exposure to ARTs in adult HIV-1 infected patients in Montreal. BMC Infect Dis 2019; 19:820.</a></li><li><a class="nounderline abstract_t">Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 1999; 13:2261.</a></li><li><a class="nounderline abstract_t">Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16:2447.</a></li><li><a class="nounderline abstract_t">Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191.</a></li><li><a class="nounderline abstract_t">Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309.</a></li><li><a class="nounderline abstract_t">Dubé MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19:1807.</a></li><li><a class="nounderline abstract_t">Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44:139.</a></li><li><a class="nounderline abstract_t">Shlay JC, Sharma S, Peng G, et al. Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine. J Acquir Immune Defic Syndr 2008; 48:53.</a></li><li><a class="nounderline abstract_t">Dubé MP, Komarow L, Mulligan K, et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr 2007; 45:508.</a></li><li><a class="nounderline abstract_t">Shlay JC, Sharma S, Peng G, et al. The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 51:298.</a></li><li><a class="nounderline abstract_t">Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251.</a></li><li><a class="nounderline abstract_t">McComsey G, Maa JF. Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy. AIDS Read 2003; 13:539.</a></li><li><a class="nounderline abstract_t">Brown TT, Chu H, Wang Z, et al. Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy. AIDS 2007; 21:1731.</a></li><li><a class="nounderline abstract_t">Sievers M, Walker UA, Sevastianova K, et al. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy. J Infect Dis 2009; 200:252.</a></li><li><a class="nounderline abstract_t">Hammond E, McKinnon E, Nolan D. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Clin Infect Dis 2010; 51:591.</a></li><li><a class="nounderline abstract_t">Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23:1109.</a></li><li><a class="nounderline abstract_t">Pérez-Molina JA, Domingo P, Martínez E, Moreno S. The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy. J Antimicrob Chemother 2008; 62:234.</a></li><li><a class="nounderline abstract_t">McComsey GA, Moser C, Currier J, et al. Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s. Clin Infect Dis 2016; 62:853.</a></li><li><a class="nounderline abstract_t">Domingo P, Gutierrez Mdel M, Gallego-Escuredo JM, et al. Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study. PLoS One 2014; 9:e89088.</a></li><li><a class="nounderline abstract_t">Tebas P, Sension M, Arribas J, et al. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials. Clin Infect Dis 2014; 59:425.</a></li><li><a class="nounderline abstract_t">Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15:1389.</a></li><li><a class="nounderline abstract_t">McDermott AY, Terrin N, Wanke C, et al. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. Clin Infect Dis 2005; 41:1662.</a></li><li><a class="nounderline abstract_t">Parker R, Komarow L, Grinspoon K, et al. Baseline and early ontreatment predictors of lipoatrophy at week 64 in a randomized trial of initial antiretroviral therapy therapy: a secondary analysis of A5005s, a substudy of ACTG 384. Antivir Ther 2005; 10(Supp 3):15.</a></li><li><a class="nounderline abstract_t">Mulligan K, Anastos K, Justman J, et al. Fat distribution in HIV-infected women in the United States: DEXA substudy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2005; 38:18.</a></li><li><a class="nounderline abstract_t">Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:245.</a></li><li><a class="nounderline abstract_t">Mallon PW, Cooper DA, Carr A. HIV-associated lipodystrophy. HIV Med 2001; 2:166.</a></li><li><a class="nounderline abstract_t">Mulligan K, Tai VW, Algren H, et al. Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 2001; 26:443.</a></li><li><a class="nounderline abstract_t">Guaraldi G, Fontdevila J, Christensen LH, et al. Surgical correction of HIV-associated facial lipoatrophy. AIDS 2011; 25:1.</a></li><li><a class="nounderline abstract_t">Power R, Tate HL, McGill SM, Taylor C. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infect 2003; 79:137.</a></li><li><a class="nounderline abstract_t">Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48.</a></li><li><a class="nounderline abstract_t">Podzamczer D, Ferrer E, Martínez E, et al. How much fat loss is needed for lipoatrophy to become clinically evident? AIDS Res Hum Retroviruses 2009; 25:563.</a></li><li><a class="nounderline abstract_t">Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 2006; 42:562.</a></li><li><a class="nounderline abstract_t">James J, Carruthers A, Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg 2002; 28:979.</a></li><li><a class="nounderline abstract_t">Burgess CM, Quiroga RM. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 2005; 52:233.</a></li><li><a class="nounderline abstract_t">Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004; 5:82.</a></li><li><a class="nounderline abstract_t">Funk E, Brissett AE, Friedman CD, Bressler FJ. HIV-associated facial lipoatrophy: establishment of a validated grading scale. Laryngoscope 2007; 117:1349.</a></li><li><a class="nounderline abstract_t">Martinez E, Mocroft A, García-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357:592.</a></li><li><a class="nounderline abstract_t">Sax PE, Kumar P. Tolerability and safety of HIV protease inhibitors in adults. J Acquir Immune Defic Syndr 2004; 37:1111.</a></li><li><a class="nounderline abstract_t">Kotler DP. HIV lipodystrophy etiology and pathogenesis. Body composition and metabolic alterations: etiology and pathogenesis. AIDS Read 2003; 13:S5.</a></li><li><a class="nounderline abstract_t">Justman JE, Hoover DR, Shi Q, et al. Longitudinal anthropometric patterns among HIV-infected and HIV-uninfected women. J Acquir Immune Defic Syndr 2008; 47:312.</a></li><li><a class="nounderline abstract_t">Aldeen T, Wells C, Hay P, et al. Lipodystrophy associated with nevirapine-containing antiretroviral therapies. AIDS 1999; 13:865.</a></li><li><a class="nounderline abstract_t">Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis 2002; 35:1219.</a></li><li><a class="nounderline abstract_t">Barreiro P, Soriano V, Blanco F, et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000; 14:807.</a></li><li><a class="nounderline abstract_t">Lake JE, McComsey GA, Hulgan T, et al.. Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity. Open Forum Infect Dis 2015; 2.</a></li><li><a class="nounderline abstract_t">Jemsek JG, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis 2006; 42:273.</a></li><li><a class="nounderline abstract_t">Shlay JC, Bartsch G, Peng G, et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr 2007; 44:506.</a></li><li><a class="nounderline abstract_t">Sax PE, Erlandson KM, Lake JE, et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis 2020; 71:1379.</a></li><li><a class="nounderline abstract_t">Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med 2019; 381:803.</a></li><li><a class="nounderline abstract_t">Taramasso L, Berruti M, Briano F, di Biagio A. The switch from TDF to TAF determines weight gain in patients on rilpivirine-based regimen. AIDS 2020.</a></li><li><a class="nounderline abstract_t">Hadigan C. Dietary habits and their association with metabolic abnormalities in human immunodeficiency virus-related lipodystrophy. Clin Infect Dis 2003; 37 Suppl 2:S101.</a></li><li><a class="nounderline abstract_t">Hendricks KM, Dong KR, Tang AM, et al. High-fiber diet in HIV-positive men is associated with lower risk of developing fat deposition. Am J Clin Nutr 2003; 78:790.</a></li><li><a class="nounderline abstract_t">Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311:158.</a></li><li><a class="nounderline abstract_t">Després JP. Health consequences of visceral obesity. Ann Med 2001; 33:534.</a></li><li><a class="nounderline abstract_t">Palella FJ Jr, McKibben R, Post WS, et al. Anatomic Fat Depots and Coronary Plaque Among Human Immunodeficiency Virus-Infected and Uninfected Men in the Multicenter AIDS Cohort Study. Open Forum Infect Dis 2016; 3:ofw098.</a></li><li><a class="nounderline abstract_t">Glesby MJ, Hanna DB, Hoover DR, et al. Abdominal Fat Depots and Subclinical Carotid Artery Atherosclerosis in Women With and Without HIV Infection. J Acquir Immune Defic Syndr 2018; 77:308.</a></li><li><a class="nounderline abstract_t">Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277:25863.</a></li><li><a class="nounderline abstract_t">Addy CL, Gavrila A, Tsiodras S, et al. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003; 88:627.</a></li><li><a class="nounderline abstract_t">Sweeney LL, Brennan AM, Mantzoros CS. The role of adipokines in relation to HIV lipodystrophy. AIDS 2007; 21:895.</a></li><li><a class="nounderline abstract_t">Nagy GS, Tsiodras S, Martin LD, et al. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis 2003; 36:795.</a></li><li><a class="nounderline abstract_t">Ranade K, Geese WJ, Noor M, et al. Genetic analysis implicates resistin in HIV lipodystrophy. AIDS 2008; 22:1561.</a></li><li><a class="nounderline abstract_t">Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409:307.</a></li><li><a class="nounderline abstract_t">Zanone Poma B, Riva A, Nasi M, et al. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS 2008; 22:1769.</a></li><li><a class="nounderline abstract_t">Nasi M, Guaraldi G, Orlando G, et al. Mitochondrial DNA haplogroups and highly active antiretroviral therapy-related lipodystrophy. Clin Infect Dis 2008; 47:962.</a></li><li><a class="nounderline abstract_t">Srinivasa S, Garcia-Martin R, Torriani M, et al. Altered pattern of circulating miRNAs in HIV lipodystrophy perturbs key adipose differentiation and inflammation pathways. JCI Insight 2021; 6.</a></li><li><a class="nounderline abstract_t">Meininger G, Hadigan C, Rietschel P, Grinspoon S. Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men. Am J Clin Nutr 2002; 76:460.</a></li><li><a class="nounderline abstract_t">Gan SK, Samaras K, Carr A, Chisholm D. Anti-retroviral therapy, insulin resistance and lipodystrophy. Diabetes Obes Metab 2001; 3:67.</a></li><li><a class="nounderline abstract_t">Currier J, Scherzer R, Bacchetti P, et al. Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. J Acquir Immune Defic Syndr 2008; 48:35.</a></li><li><a class="nounderline abstract_t">Wohl D, Scherzer R, Heymsfield S, et al. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. J Acquir Immune Defic Syndr 2008; 48:44.</a></li></ol></div><div id="topicVersionRevision">Topic 3733 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2910092" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hypertriglyceridemia in the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12799406" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Impact of HIV infection and HAART on serum lipids in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12870540" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10708054" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16186728" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Fat distribution in men with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16186727" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Morphologic changes in HIV-infected men: sorting fact from fiction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16652032" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16886161" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9652687" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9619798" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10449280" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Epidemiological and clinical aspects of the metabolic complications of HIV infection the fat redistribution syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12700446" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10770555" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The development of lipodystrophy on a protease inhibitor-sparing highly active antiretroviral therapy regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9803975" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Body shape changes in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11216932" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15909274" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12514413" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657755" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31533648" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Association between lipodystrophy and length of exposure to ARTs in adult HIV-1 infected patients in Montreal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10563711" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12461419" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249568" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10930144" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16227788" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17106274" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18491421" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17589373" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19412117" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421366" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14649623" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17690571" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19519254" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20645860" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19417580" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18480167" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26797215" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24586518" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24729492" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11504960" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical assessment of HIV-associated lipodystrophy in an ambulatory population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16267741" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Baseline and early ontreatment predictors of lipoatrophy at week 64 in a randomized trial of initial antiretroviral therapy therapy: a secondary analysis of A5005s, a substudy of ACTG 384</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15608519" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Fat distribution in HIV-infected women in the United States: DEXA substudy in the Women's Interagency HIV Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11464143" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11737397" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : HIV-associated lipodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11391163" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20975513" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Surgical correction of HIV-associated facial lipoatrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12690137" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15635112" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cardiovascular risk and body-fat abnormalities in HIV-infected adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19500014" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : How much fat loss is needed for lipoatrophy to become clinically evident?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16837863" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Fat distribution in women with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12460289" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : HIV-associated facial lipoatrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15692467" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15012646" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17607150" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : HIV-associated facial lipoatrophy: establishment of a validated grading scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11558485" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15319670" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Tolerability and safety of HIV protease inhibitors in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12762287" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : HIV lipodystrophy etiology and pathogenesis. Body composition and metabolic alterations: etiology and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18197125" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Longitudinal anthropometric patterns among HIV-infected and HIV-uninfected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10357391" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Lipodystrophy associated with nevirapine-containing antiretroviral therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12410482" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Switching effective antiretroviral therapy: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10839588" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16355341" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17325603" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31606734" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31339677" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32028332" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The switch from TDF to TAF determines weight gain in patients on rilpivirine-based regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12942382" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Dietary habits and their association with metabolic abnormalities in human immunodeficiency virus-related lipodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14522738" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : High-fiber diet in HIV-positive men is associated with lower risk of developing fat deposition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7613427" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Waist circumference as a measure for indicating need for weight management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11730160" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Health consequences of visceral obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27419170" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Anatomic Fat Depots and Coronary Plaque Among Human Immunodeficiency Virus-Infected and Uninfected Men in the Multicenter AIDS Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29210836" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Abdominal Fat Depots and Subclinical Carotid Artery Atherosclerosis in Women With and Without HIV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12032136" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Disruption of adiponectin causes insulin resistance and neointimal formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12574192" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17457082" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The role of adipokines in relation to HIV lipodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12627366" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18670214" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Genetic analysis implicates resistin in HIV lipodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11201732" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The hormone resistin links obesity to diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18753860" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18752438" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Mitochondrial DNA haplogroups and highly active antiretroviral therapy-related lipodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34383714" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Altered pattern of circulating miRNAs in HIV lipodystrophy perturbs key adipose differentiation and inflammation pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12145023" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11298728" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Anti-retroviral therapy, insulin resistance and lipodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18197118" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18360291" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
